25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Processa Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyze Processa Pharmaceuticals Inc together

I guess you are interested in Processa Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Processa Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Processa Pharmaceuticals Inc

I send you an email if I find something interesting about Processa Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Processa Pharmaceuticals Inc (30 sec.)










1.2. What can you expect buying and holding a share of Processa Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
5.0%

What is your share worth?

Current worth
$1.14
Expected worth in 1 year
$1.74
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$0.60
Return On Investment
59.6%

For what price can you sell your share?

Current Price per Share
$1.02
Expected price per share
$0.85 - $1.42
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Processa Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)
$1.02
Intrinsic Value Per Share
$-58.24 - $-22.04
Total Value Per Share
$-57.11 - $-20.90

2.2. Growth of Processa Pharmaceuticals Inc (5 min.)




Is Processa Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$3.7m$8.4m-$2.5m-43.7%

How much money is Processa Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$2.8m-$9.7m$6.8m237.9%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Processa Pharmaceuticals Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#716 / 949

Most Revenue
#806 / 949

Most Profit
#346 / 949

Most Efficient
#195 / 949
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Processa Pharmaceuticals Inc?

Welcome investor! Processa Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Processa Pharmaceuticals Inc.

First you should know what it really means to hold a share of Processa Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Processa Pharmaceuticals Inc is $1.015. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Processa Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Processa Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.14. Based on the TTM, the Book Value Change Per Share is $0.15 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.13 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Processa Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.03-101.8%-0.88-86.8%-0.18-18.1%-0.40-39.4%-0.27-26.7%
Usd Book Value Change Per Share-0.71-69.8%0.1514.9%-0.13-13.1%-0.02-2.1%0.032.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.71-69.8%0.1514.9%-0.13-13.1%-0.02-2.1%0.032.9%
Usd Price Per Share1.37-1.58-0.59-5.14-3.35-
Price to Earnings Ratio-0.33--0.44--0.83--5.84--6.79-
Price-to-Total Gains Ratio-1.93--0.54--1.17--25.03--19.72-
Price to Book Ratio1.21-0.88-1.05-3.65-5.05-
Price-to-Total Gains Ratio-1.93--0.54--1.17--25.03--19.72-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.015
Number of shares985
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.15-0.02
Usd Total Gains Per Share0.15-0.02
Gains per Quarter (985 shares)148.95-21.35
Gains per Year (985 shares)595.80-85.42
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
105965860-85-95
20119211820-171-180
30178717780-256-265
40238323740-342-350
50297929700-427-435
60357535660-512-520
70417141620-598-605
80476647580-683-690
90536253540-769-775
100595859500-854-860

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.052.00.00.0%
Book Value Change Per Share2.02.00.050.0%3.09.00.025.0%5.015.00.025.0%10.027.03.025.0%12.034.06.023.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%2.00.038.05.0%5.00.047.09.6%
Total Gains per Share2.02.00.050.0%3.09.00.025.0%5.015.00.025.0%10.027.03.025.0%12.034.06.023.1%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Processa Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.7080.151-568%-0.133-81%-0.022-97%0.029-2518%
Book Value Per Share--1.1361.806-37%0.639+78%1.378-18%0.823+38%
Current Ratio--3.9686.549-39%8.919-56%9.389-58%5.256-24%
Debt To Asset Ratio--0.2470.175+41%0.131+89%0.151+63%61.522-100%
Debt To Equity Ratio--0.3280.217+51%0.152+116%0.201+64%1.632-80%
Dividend Per Share----0%-0%-0%0.000-100%
Enterprise Value--6158214.2609514277.271-35%15344656.876-60%59136383.389-90%39926388.669-85%
Eps---1.033-0.881-15%-0.184-82%-0.399-61%-0.271-74%
Ev To Ebitda Ratio---0.455-0.816+79%0.064-815%-8.079+1676%-7.044+1449%
Ev To Sales Ratio--infinfnan%infnan%infnan%nannan%
Free Cash Flow Per Share---1.101-0.851-23%-0.155-86%-0.281-74%-0.184-83%
Free Cash Flow To Equity Per Share---0.818-0.303-63%-0.018-98%-0.031-96%-0.020-98%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.047-5%
Intrinsic Value_10Y_max---22.039--------
Intrinsic Value_10Y_min---58.241--------
Intrinsic Value_1Y_max---0.950--------
Intrinsic Value_1Y_min---2.290--------
Intrinsic Value_3Y_max---3.814--------
Intrinsic Value_3Y_min---9.993--------
Intrinsic Value_5Y_max---7.833--------
Intrinsic Value_5Y_min---21.047--------
Market Cap3315944.100-35%4488117.2605156373.521-13%8470129.376-47%51594389.439-91%29681685.477-85%
Net Profit Margin----0%-0%0.844-100%-17.0540%
Operating Margin----0%-0%-0.2950%-13.5580%
Operating Ratio----0%-0%0.246-100%13.868-100%
Pb Ratio0.894-35%1.2060.877+37%1.047+15%3.652-67%5.051-76%
Pe Ratio-0.246+26%-0.332-0.440+33%-0.831+151%-5.838+1661%-6.791+1949%
Price Per Share1.015-35%1.3701.577-13%0.587+133%5.140-73%3.346-59%
Price To Free Cash Flow Ratio-0.231+26%-0.311-0.482+55%-0.944+203%15.313-102%2.622-112%
Price To Total Gains Ratio-1.434+26%-1.935-0.543-72%-1.174-39%-25.031+1194%-19.717+919%
Quick Ratio--2.3725.313-55%7.588-69%8.309-71%4.612-49%
Return On Assets---0.685-0.443-35%-1.124+64%-0.414-40%-2.518+268%
Return On Equity---0.910-0.550-40%-1.292+42%-0.491-46%-1.132+24%
Total Gains Per Share---0.7080.151-568%-0.133-81%-0.022-97%0.029-2504%
Usd Book Value--3720785.0005904243.500-37%8485137.750-56%14084696.250-74%8067166.975-54%
Usd Book Value Change Per Share---0.7080.151-568%-0.133-81%-0.022-97%0.029-2518%
Usd Book Value Per Share--1.1361.806-37%0.639+78%1.378-18%0.823+38%
Usd Dividend Per Share----0%-0%-0%0.000-100%
Usd Eps---1.033-0.881-15%-0.184-82%-0.399-61%-0.271-74%
Usd Free Cash Flow---3605851.000-2781108.250-23%-2109909.750-41%-2002290.150-44%-1205640.800-67%
Usd Free Cash Flow Per Share---1.101-0.851-23%-0.155-86%-0.281-74%-0.184-83%
Usd Free Cash Flow To Equity Per Share---0.818-0.303-63%-0.018-98%-0.031-96%-0.020-98%
Usd Market Cap3315944.100-35%4488117.2605156373.521-13%8470129.376-47%51594389.439-91%29681685.477-85%
Usd Price Per Share1.015-35%1.3701.577-13%0.587+133%5.140-73%3.346-59%
Usd Profit---3384703.000-2881585.250-15%-9735932.750+188%-4572603.800+35%-2659965.625-21%
Usd Revenue----0%-0%-5127.5000%1640.391-100%
Usd Total Gains Per Share---0.7080.151-568%-0.133-81%-0.022-97%0.029-2504%
 EOD+3 -5MRQTTM+2 -30YOY+6 -255Y+7 -2710Y+12 -24

3.3 Fundamental Score

Let's check the fundamental score of Processa Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.246
Price to Book Ratio (EOD)Between0-10.894
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.372
Current Ratio (MRQ)Greater than13.968
Debt to Asset Ratio (MRQ)Less than10.247
Debt to Equity Ratio (MRQ)Less than10.328
Return on Equity (MRQ)Greater than0.15-0.910
Return on Assets (MRQ)Greater than0.05-0.685
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Processa Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.049
Ma 20Greater thanMa 501.024
Ma 50Greater thanMa 1001.183
Ma 100Greater thanMa 2001.363
OpenGreater thanClose1.050
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Processa Pharmaceuticals Inc

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.

Fundamental data was last updated by Penke on 2024-11-15 22:26:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Processa Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Processa Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Processa Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y84.4%-84.4%
5Y84.4%10Y-1,705.4%+1,789.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--112.2%+112.2%
TTM--221.4%+221.4%
YOY--210.0%+210.0%
5Y84.4%-342.2%+426.6%
10Y-1,705.4%-464.5%-1,240.9%
4.3.1.2. Return on Assets

Shows how efficient Processa Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Processa Pharmaceuticals Inc to the Biotechnology industry mean.
  • -68.5% Return on Assets means that Processa Pharmaceuticals Inc generated $-0.68 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Processa Pharmaceuticals Inc:

  • The MRQ is -68.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -44.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-68.5%TTM-44.3%-24.2%
TTM-44.3%YOY-112.4%+68.1%
TTM-44.3%5Y-41.4%-2.8%
5Y-41.4%10Y-251.8%+210.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-68.5%-11.3%-57.2%
TTM-44.3%-11.7%-32.6%
YOY-112.4%-11.3%-101.1%
5Y-41.4%-12.7%-28.7%
10Y-251.8%-14.1%-237.7%
4.3.1.3. Return on Equity

Shows how efficient Processa Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Processa Pharmaceuticals Inc to the Biotechnology industry mean.
  • -91.0% Return on Equity means Processa Pharmaceuticals Inc generated $-0.91 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Processa Pharmaceuticals Inc:

  • The MRQ is -91.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -55.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-91.0%TTM-55.0%-36.0%
TTM-55.0%YOY-129.2%+74.2%
TTM-55.0%5Y-49.1%-5.8%
5Y-49.1%10Y-113.2%+64.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-91.0%-14.2%-76.8%
TTM-55.0%-15.9%-39.1%
YOY-129.2%-14.3%-114.9%
5Y-49.1%-18.5%-30.6%
10Y-113.2%-19.3%-93.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Processa Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Processa Pharmaceuticals Inc is operating .

  • Measures how much profit Processa Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Processa Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Processa Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-29.5%+29.5%
5Y-29.5%10Y-1,355.8%+1,326.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--222.9%+222.9%
TTM--310.7%+310.7%
YOY--223.5%+223.5%
5Y-29.5%-387.1%+357.6%
10Y-1,355.8%-498.5%-857.3%
4.3.2.2. Operating Ratio

Measures how efficient Processa Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Processa Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y0.246-0.246
5Y0.24610Y13.868-13.622
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.465-2.465
TTM-3.253-3.253
YOY-3.298-3.298
5Y0.2464.788-4.542
10Y13.8686.494+7.374
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Processa Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Processa Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.97 means the company has $3.97 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Processa Pharmaceuticals Inc:

  • The MRQ is 3.968. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.549. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.968TTM6.549-2.580
TTM6.549YOY8.919-2.370
TTM6.5495Y9.389-2.841
5Y9.38910Y5.256+4.134
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.9683.637+0.331
TTM6.5493.890+2.659
YOY8.9194.666+4.253
5Y9.3895.953+3.436
10Y5.2566.277-1.021
4.4.3.2. Quick Ratio

Measures if Processa Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Processa Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 2.37 means the company can pay off $2.37 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Processa Pharmaceuticals Inc:

  • The MRQ is 2.372. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 5.313. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.372TTM5.313-2.941
TTM5.313YOY7.588-2.275
TTM5.3135Y8.309-2.996
5Y8.30910Y4.612+3.697
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.3723.086-0.714
TTM5.3133.451+1.862
YOY7.5884.456+3.132
5Y8.3095.931+2.378
10Y4.6126.436-1.824
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Processa Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Processa Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Processa Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.25 means that Processa Pharmaceuticals Inc assets are financed with 24.7% credit (debt) and the remaining percentage (100% - 24.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Processa Pharmaceuticals Inc:

  • The MRQ is 0.247. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.175. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.247TTM0.175+0.072
TTM0.175YOY0.131+0.044
TTM0.1755Y0.151+0.023
5Y0.15110Y61.522-61.370
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2470.350-0.103
TTM0.1750.344-0.169
YOY0.1310.310-0.179
5Y0.1510.365-0.214
10Y61.5220.382+61.140
4.5.4.2. Debt to Equity Ratio

Measures if Processa Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Processa Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 32.8% means that company has $0.33 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Processa Pharmaceuticals Inc:

  • The MRQ is 0.328. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.217. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.328TTM0.217+0.111
TTM0.217YOY0.152+0.065
TTM0.2175Y0.201+0.017
5Y0.20110Y1.632-1.431
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3280.394-0.066
TTM0.2170.432-0.215
YOY0.1520.380-0.228
5Y0.2010.451-0.250
10Y1.6320.490+1.142
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Processa Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Processa Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -0.33 means the investor is paying $-0.33 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Processa Pharmaceuticals Inc:

  • The EOD is -0.246. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.332. Based on the earnings, the company is expensive. -2
  • The TTM is -0.440. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.246MRQ-0.332+0.086
MRQ-0.332TTM-0.440+0.109
TTM-0.440YOY-0.831+0.391
TTM-0.4405Y-5.838+5.398
5Y-5.83810Y-6.791+0.953
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.246-2.253+2.007
MRQ-0.332-2.411+2.079
TTM-0.440-3.149+2.709
YOY-0.831-3.274+2.443
5Y-5.838-6.143+0.305
10Y-6.791-6.785-0.006
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Processa Pharmaceuticals Inc:

  • The EOD is -0.231. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.311. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.482. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.231MRQ-0.311+0.081
MRQ-0.311TTM-0.482+0.171
TTM-0.482YOY-0.944+0.462
TTM-0.4825Y15.313-15.795
5Y15.31310Y2.622+12.691
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.231-3.009+2.778
MRQ-0.311-3.259+2.948
TTM-0.482-3.730+3.248
YOY-0.944-4.574+3.630
5Y15.313-8.371+23.684
10Y2.622-9.287+11.909
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Processa Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.21 means the investor is paying $1.21 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Processa Pharmaceuticals Inc:

  • The EOD is 0.894. Based on the equity, the company is cheap. +2
  • The MRQ is 1.206. Based on the equity, the company is underpriced. +1
  • The TTM is 0.877. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.894MRQ1.206-0.313
MRQ1.206TTM0.877+0.329
TTM0.877YOY1.047-0.170
TTM0.8775Y3.652-2.775
5Y3.65210Y5.051-1.399
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.8941.979-1.085
MRQ1.2062.051-0.845
TTM0.8772.365-1.488
YOY1.0472.455-1.408
5Y3.6523.726-0.074
10Y5.0514.378+0.673
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Processa Pharmaceuticals Inc.

4.8.1. Institutions holding Processa Pharmaceuticals Inc

Institutions are holding 1.451% of the shares of Processa Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-06-30Vanguard Group Inc0.750202443300
2024-06-30Geode Capital Management, LLC0.5292017237172370
2024-06-30Tower Research Capital LLC0.09210.00012999-1506-33.4295
2024-06-30Wells Fargo & Co0.00470154-16-9.4118
2024-06-30Main Street Group Ltd0.00310.000110000
2024-09-30Hanson Mcclain Inc0.002608500
2024-06-30Bank of America Corp0.0006021-139-86.875
2024-06-30Royal Bank of Canada0.00010400
2024-09-30Absolute Investment Management LLC00100
2024-06-30Sabby Management LLC000-48601-100
2024-06-30UBS Group AG000-4181-100
2024-06-30Citadel Advisors Llc000-8311-100
2024-06-30Two Sigma Investments LLC000-24096-100
Total 1.38260.000245034-69613-154.6%

4.9.2. Funds holding Processa Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Vanguard Institutional Extnd Mkt Idx Tr0.747902443300
2024-09-30Fidelity Extended Market Index0.52770.000117240270118.5776
2024-09-30Fidelity Series Total Market Index0.03870126500
2024-09-30Northern Trust Extended Eq Market Idx0.03210104800
2024-09-30NT Ext Equity Mkt Idx Fd - L0.03210104800
2024-09-30Fidelity Nasdaq Composite Index0.0169055300
2024-10-31State St US Extended Mkt Indx NL Cl C0.0164053500
2024-09-30Fidelity Total Market Index0.0135044100
2024-09-30NT Ext Equity Mkt Idx Fd - NL0.0096031200
2024-09-30NT Ext Equity Mkt Idx Fd - DC - NL - T20.0077025110.4
2024-06-30SSgA U.S. Total Market Index Strategy0.006702196542.2078
2024-09-30Spartan Total Market Index Pool E0.0059019400
2024-09-30NT Ext Eq Mkt Indx Fd DC Lending Tier 50.005016200
2024-10-31State St US Ttl Mkt Indx SL Cl I0.00206500
2024-09-30Northern Trust Wilshire 50000.001404600
Total 1.46360.000147812+2767+5.8%

5.3. Insider Transactions

Insiders are holding 8.736% of the shares of Processa Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-02-07David YoungBUY210002.45
2024-01-31Patrick LinBUY25002.37
2024-01-30George K NgBUY100002.7
2024-01-30Justin W YorkeBUY80002.69
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets4,942
Total Liabilities1,221
Total Stockholder Equity3,721
 As reported
Total Liabilities 1,221
Total Stockholder Equity+ 3,721
Total Assets = 4,942

Assets

Total Assets4,942
Total Current Assets4,838
Long-term Assets104
Total Current Assets
Cash And Cash Equivalents 2,891
Other Current Assets 1,947
Total Current Assets  (as reported)4,838
Total Current Assets  (calculated)4,838
+/-0
Long-term Assets
Property Plant Equipment 98
Long-term Assets Other 6
Long-term Assets  (as reported)104
Long-term Assets  (calculated)104
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities1,219
Long-term Liabilities2
Total Stockholder Equity3,721
Total Current Liabilities
Short-term Debt 95
Accounts payable 712
Other Current Liabilities 413
Total Current Liabilities  (as reported)1,219
Total Current Liabilities  (calculated)1,219
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)2
Long-term Liabilities  (calculated)0
+/- 2
Total Stockholder Equity
Common Stock0
Retained Earnings -84,490
Other Stockholders Equity 88,211
Total Stockholder Equity (as reported)3,721
Total Stockholder Equity (calculated)3,721
+/-0
Other
Cash and Short Term Investments 2,891
Common Stock Shares Outstanding 3,276
Liabilities and Stockholders Equity 4,942
Net Debt -2,795
Net Working Capital 3,619
Short Long Term Debt Total 97



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-31
> Total Assets 
0
0
0
4,352
3,884
3,185
3,467
3,843
2,938
2,908
2,785
2,667
2,542
2,542
878
498
498
47
43
35
3
104
47
2
2,983
2,983
14,438
13,463
13,215
12,078
11,306
10,821
10,883
10,012
10,011
9,589
25,214
33,338
31,138
29,025
26,464
24,301
21,658
18,604
8,620
12,432
10,090
8,083
5,787
9,945
7,601
4,942
4,9427,6019,9455,7878,08310,09012,4328,62018,60421,65824,30126,46429,02531,13833,33825,2149,58910,01110,01210,88310,82111,30612,07813,21513,46314,4382,9832,98324710433543474984988782,5422,5422,6672,7852,9082,9383,8433,4673,1853,8844,352000
   > Total Current Assets 
0
0
0
1,536
1,157
554
938
1,313
515
478
466
401
379
379
479
323
323
47
43
35
3
104
47
2
2,952
2,952
3,594
2,801
2,020
1,543
990
725
1,007
357
577
376
16,203
24,546
22,566
20,670
18,327
16,384
13,961
10,887
8,387
12,219
9,897
7,907
5,632
9,800
7,478
4,838
4,8387,4789,8005,6327,9079,89712,2198,38710,88713,96116,38418,32720,67022,56624,54616,2033765773571,0077259901,5432,0202,8013,5942,9522,95224710433543473233234793793794014664785151,3139385541,1571,536000
       Cash And Cash Equivalents 
0
0
0
1,392
1,027
421
630
1,002
187
82
40
56
21
21
15
15
15
2
15
7
3
2
2
2
2,847
2,847
2,850
2,424
1,741
1,249
722
504
692
142
453
325
15,416
23,048
20,831
19,093
16,498
14,395
12,064
9,055
6,504
10,742
8,677
6,861
4,706
8,920
5,571
2,891
2,8915,5718,9204,7066,8618,67710,7426,5049,05512,06414,39516,49819,09320,83123,04815,4163254531426925047221,2491,7412,4242,8502,8472,8472223715215151521215640821871,0026304211,0271,392000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
496
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000049600000000000000000000000000
       Net Receivables 
0
0
0
49
30
20
61
24
19
20
99
27
4
4
104
12
12
25
25
25
0
0
25
9
63
63
164
95
22
47
0
1
0
28
26
8
232
74
70
70
70
0
0
0
0
0
0
0
0
22
0
0
0022000000007070707423282628010472295164636392500252525121210444279920192461203049000
       Other Current Assets 
0
0
0
48
50
50
48
80
80
112
121
117
0
132
33
6
0
20
4
4
0
48
1
0
0
41
84
282
258
247
268
220
316
186
98
43
555
1,424
1,664
1,507
1,759
1,989
1,897
1,832
1,883
1,478
1,220
1,047
926
858
1,907
1,947
1,9471,9078589261,0471,2201,4781,8831,8321,8971,9891,7591,5071,6641,42455543981863162202682472582828441001480442006331320117121112808048505048000
   > Long-term Assets 
0
0
0
2,816
2,727
2,631
2,530
2,530
2,423
2,429
2,319
2,266
0
2,163
399
176
176
0
0
0
0
0
0
0
0
31
10,844
10,662
10,461
10,535
10,316
10,096
9,876
9,656
9,435
9,213
9,012
8,792
8,572
8,355
8,136
7,917
7,697
7,718
233
213
193
175
154
144
123
104
1041231441541751932132337,7187,6977,9178,1368,3558,5728,7929,0129,2139,4359,6569,87610,09610,31610,53510,46110,66210,84431000000001761763992,16302,2662,3192,4292,4232,5302,5302,6312,7272,816000
       Property Plant Equipment 
0
0
0
316
316
310
297
387
370
465
444
480
0
466
399
176
0
0
0
0
0
0
0
4
4
26
22
19
17
291
270
249
228
206
184
162
159
138
117
96
74
52
29
247
228
208
188
170
149
139
117
98
9811713914917018820822824729527496117138159162184206228249270291171922264400000001763994660480444465370387297310316316000
       Intangible Assets 
0
0
0
2,500
2,411
2,321
2,232
2,143
2,054
1,964
1,875
1,786
1,696
1,696
0
0
0
0
0
0
0
0
0
0
0
11,013
10,816
10,637
10,438
10,239
10,040
9,841
9,642
9,444
9,245
9,046
8,847
8,648
8,449
8,254
8,057
7,860
7,662
7,465
0
0
0
0
0
0
0
0
000000007,4657,6627,8608,0578,2548,4498,6488,8479,0469,2459,4449,6429,84110,04010,23910,43810,63710,81611,013000000000001,6961,6961,7861,8751,9642,0542,1432,2322,3212,4112,500000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
6
734
6
6
6
6
6
6
6
164
6
6
6
6
6
6
6
0
0
6
0
0
0
0
0
00000600666666616466666667346111100000000000000000000000
> Total Liabilities 
0
0
0
1,296
1,322
1,449
2,457
1,466
1,267
1,878
2,162
2,783
1,334
1,334
2,198
2,116
2,116
2,165
2,214
2,285
2,354
2,083
2,165
2,439
2,610
2,610
3,131
2,957
3,514
2,954
2,804
2,151
2,871
2,778
3,418
4,062
2,275
2,002
1,896
1,817
978
1,064
1,576
1,364
1,149
2,290
931
915
797
1,061
1,577
1,221
1,2211,5771,0617979159312,2901,1491,3641,5761,0649781,8171,8962,0022,2754,0623,4182,7782,8712,1512,8042,9543,5142,9573,1312,6102,6102,4392,1652,0832,3542,2852,2142,1652,1162,1162,1981,3341,3342,7832,1621,8781,2671,4662,4571,4491,3221,296000
   > Total Current Liabilities 
0
0
0
181
716
1,100
2,365
1,310
1,122
785
562
809
840
840
2,093
2,089
2,089
2,165
2,214
2,285
2,354
2,083
2,165
2,439
2,600
2,600
650
691
646
725
783
292
1,192
1,246
1,898
2,658
1,221
1,096
1,161
1,226
971
1,058
1,571
1,193
999
2,161
821
826
731
1,011
1,552
1,219
1,2191,5521,0117318268212,1619991,1931,5711,0589711,2261,1611,0961,2212,6581,8981,2461,1922927837256466916502,6002,6002,4392,1652,0832,3542,2852,2142,1652,0892,0892,0938408408095627851,1221,3102,3651,100716181000
       Short-term Debt 
0
0
0
27
527
777
2,018
1,040
631
542
294
535
466
466
1,585
1,626
1,626
1,382
1,612
1,612
1,612
1,366
1,382
1,612
2,449
2,449
224
228
230
289
308
77
880
882
1,449
1,632
205
242
92
93
71
49
27
76
79
81
82
83
167
90
186
95
9518690167838281797627497193922422051,6321,449882880773082892302282242,4492,4491,6121,3821,3661,6121,6121,6121,3821,6261,6261,5854664665352945426311,0402,01877752727000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
230
230
0
803
804
1,377
1,553
118
145
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000001451181,5531,377804803023023000000000000000000000000000000
       Accounts payable 
0
0
0
102
73
161
233
101
77
83
112
145
0
190
219
191
0
169
174
171
0
159
169
179
8
51
251
80
292
283
143
65
76
93
73
427
321
177
288
355
219
316
648
311
328
317
239
346
312
455
953
712
7129534553123462393173283116483162193552881773214277393766514328329280251518179169159017117416901912191900145112837710123316173102000
       Other Current Liabilities 
0
0
0
52
115
162
114
168
258
160
155
130
0
125
124
249
0
614
427
502
0
300
307
92
0
101
174
383
124
59
333
149
235
272
376
598
695
676
781
779
681
693
896
805
592
1,763
501
397
252
466
412
413
4134124662523975011,7635928058966936817797816766955983762722351493335912438317410109230730005024276140249124125013015516025816811416211552000
   > Long-term Liabilities 
0
0
0
1,115
606
349
92
156
145
1,094
1,600
1,974
0
494
105
28
28
0
0
0
0
0
0
0
0
10
2,481
2,266
2,868
2,229
2,020
1,859
1,679
1,532
1,521
1,404
1,054
906
735
591
7
6
5
172
151
129
109
89
67
51
26
2
2265167891091291511725675917359061,0541,4041,5211,5321,6791,8592,0202,2292,8682,2662,4811000000000282810549401,9741,6001,094145156923496061,115000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
45
18
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000001845000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
2
440
372
2,266
2,134
2,004
1,833
1,692
1,532
1,404
1,316
1,245
931
841
704
582
0
0
0
0
0
0
0
0
0
0
0
0
0000000000005827048419311,2451,3161,4041,5321,6921,8332,0042,1342,2663724402100000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
531
441
304
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000304441531000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
3,056
2,562
1,735
1,010
2,377
1,671
1,030
623
-117
0
1,208
-1,320
-1,618
0
-2,118
-2,170
-2,250
0
-1,979
-2,118
-2,437
57
373
11,307
10,506
9,701
9,124
8,502
8,671
8,013
7,234
6,593
5,527
22,939
31,336
29,242
27,208
25,485
23,237
20,082
17,240
7,471
10,142
9,160
7,168
4,989
8,883
6,024
3,721
3,7216,0248,8834,9897,1689,16010,1427,47117,24020,08223,23725,48527,20829,24231,33622,9395,5276,5937,2348,0138,6718,5029,1249,70110,50611,30737357-2,437-2,118-1,9790-2,250-2,170-2,1180-1,618-1,3201,2080-1176231,0301,6712,3771,0101,7352,5623,056000
   Common Stock
0
0
0
0
0
0
1
1
1
1
1
1
0
1
1
1
0
1
1
1
0
1
1
1
1
4
4
4
4
4
4
4
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
2
0
0
0
0
0000222222222221111144444441111011101110111111000000
   Retained Earnings Total Equity0000000000000-30,652-27,495-25,396000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000-22-20-18-1600-10-7-3-3-19-19-19-19-19-19-19-172-172-243-186-186-149-127-103-77-60-46-32-19-6000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
48,334
58,830
59,892
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000059,89258,83048,334000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
5,672
6,012
6,044
6,088
8,395
8,561
9,351
9,879
10,034
0
14,298
14,544
14,482
0
12,917
12,922
12,922
0
12,914
12,917
12,903
0
4,232
17,472
17,527
17,321
17,495
17,858
18,892
19,014
19,112
19,182
21,188
48,334
58,830
59,892
60,846
62,307
63,286
65,295
68,474
71,717
78,409
80,039
80,130
80,358
86,979
87,129
88,211
88,21187,12986,97980,35880,13080,03978,40971,71768,47465,29563,28662,30760,84659,89258,83048,33421,18819,18219,11219,01418,89217,85817,49517,32117,52717,4724,232012,90312,91712,914012,92212,92212,917014,48214,54414,298010,0349,8799,3518,5618,3956,0886,0446,0125,672000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.